Views & Analysis Transparently opaque: drug list prices versus net prices The pros and cons of keeping drug pricing agreements confidential.
Views & Analysis Demonstrating value – the future for market access With the US joining other countries around the world in demanding definitions and measurements of the value of treatments, the pharma industry faces the challenge of understanding the requireme
Views & Analysis Hung parliament: who will pharma negotiate with on new PPRS? Who could influence the makeup of the new PPRS?
Views & Analysis New UK law to control generic drug prices - implications for... The aims and implications of the Health Service Medical Supplies (Costs) Act 2017.
Views & Analysis Budget impact and cost effectiveness: Can the UK learn from ... Leela Barham examines the approach of the Institute for Clinical and Economic Review.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
